Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

被引：0
|
作者：
Norman, A. [1 ]
Wee, C. [1 ]
Hobday, T. [1 ]
Kendi, A. [1 ]
Johnson, G. [1 ]
Thorpe, M. [1 ]
Lunn, B. [1 ]
Bach, C. [1 ]
Eiring, R. [1 ]
Halfdanarson, T. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2021年 / 33卷
关键词：
midpoint imaging; prrt; clinical decision making;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K25
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [41] Quality of life in patients with midgut NET following peptide receptor radionuclide therapy
    Milka Marinova
    Martin Mücke
    Felix Fischer
    Markus Essler
    Henning Cuhls
    Lukas Radbruch
    Shiwa Ghaei
    Rupert Conrad
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 2252 - 2259
  • [42] Quality of life in patients with midgut NET following peptide receptor radionuclide therapy
    Marinova, Milka
    Muecke, Martin
    Fischer, Felix
    Essler, Markus
    Cuhls, Henning
    Radbruch, Lukas
    Ghaei, Shiwa
    Conrad, Rupert
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (11) : 2252 - 2259
  • [43] The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs).
    Naraev, Boris
    Sharma, Nancy
    Engelman, Eric Steven
    Bushnell, David L.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors
    Yalchin, Mehmet
    Oliveira, Amelia
    Theocharidou, Eleni
    Pencharz, Deborah
    Navalkissoor, Shaunak
    Quigley, Ann-Marie
    Walker, Martin
    Caplin, Martyn
    Toumpanakis, Christos
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (03) : E135 - E141
  • [45] Analysis of outcomes of peptide receptor radionuclide therapy as a third line therapy in patients with advanced neuroendocrine tumors
    Velickovic, F.
    Vlajkovic, M.
    Stevic, M.
    Andjelkovic, T.
    Topic, N.
    Macut, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S936 - S936
  • [46] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [47] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [48] Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
    Miotto, M.
    Nessi, C.
    Cingarlini, S.
    Severi, S.
    Paganelli, G.
    Malleo, G.
    D'Onofrio, M.
    Pea, A.
    Vincenzi, S.
    Scarpa, A.
    Salvia, R.
    Landoni, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 254 - 254
  • [49] PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH METASTATIC NEUROENDOCRINE TUMORS: THE UNIVERSITY GENERAL HOSPITAL OF ATHENS "ATTIKON" PARADIGM
    Liotsou, T.
    Stefanoyiannis, A. P.
    Chatziioannou, S. N.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6031 - 6031
  • [50] Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 171 - 171
12345